Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.57 |
| ▸ | CASP1 | P29466 | 4/20 | 0.57 |
| ▸ | CASP9 | P55211 | 4/20 | 0.57 |
| ▸ | CASP6 | P55212 | 2/20 | 0.57 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.57 |
| ▸ | CASP4 | P49662 | 1/20 | 0.57 |
| ▸ | CASP5 | P51878 | 1/20 | 0.57 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612356 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL20257265 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133285 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133287 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL28714127 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL29449496 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL17814784 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL20257264 | 0.94 | CASP3 (0.56) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133258 | 0.92 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133257 | 0.92 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| EP-3312273-B1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | UNIV TOKYO SCIENCE FOUND (JP) | 2024-07-24 | — | — | EP | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11459586-B2 | Methods for increasing efficiency of nuclease-mediated gene editing in stem cells | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | CASP3 626/4885CASP1 919/4885CASP9 1215/4885 |
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP6, CASP1, CASP3 | CASP3 3/4885CASP1 2/4885CASP9 11/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | CASP3 626/4885CASP1 919/4885CASP9 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.